Galmed Pharmaceuticals (GLMD) Cash & Equivalents (2013 - 2025)

Galmed Pharmaceuticals' Cash & Equivalents history runs 13 years deep, the most recent figure standing at $4.0 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 14.34% year-over-year to $4.0 million; the TTM figure through Dec 2025 stood at $4.0 million (down 14.34% YoY), while the FY2025 annual figure was $4.0 million, down 14.34% from the prior year.
• Cash & Equivalents was $4.0 million for Q4 2025 at Galmed Pharmaceuticals, up from $3.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $13.4 million in Q1 2021 to a low of $1.0 million in Q2 2023.
• Historically, Cash & Equivalents has averaged $4.1 million across 5 years, with a median of $3.5 million in 2021.
• The sharpest annual moves came in 2021 and 2024: Cash & Equivalents plunged 79.18% in 2021, then soared 508.89% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $2.9 million in 2021, then tumbled by 30.1% to $2.0 million in 2022, then surged by 41.91% to $2.9 million in 2023, then soared by 62.6% to $4.7 million in 2024, then declined by 14.34% to $4.0 million in 2025.
• The last three Cash & Equivalents figures came in at $4.0 million (Q4 2025), $3.4 million (Q3 2025), and $5.0 million (Q2 2025), per Business Quant data.